MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

Search

Lantheus Holdings Inc

Închisă

SectorSănătate

74.19 -8.72

Rezumat

Modificarea prețului

24h

Curent

Minim

68.62

Maxim

81.15

Indicatori cheie

By Trading Economics

Venit

85M

73M

Vânzări

-18M

373M

P/E

Medie Sector

23.664

39.857

Marjă de profit

19.569

Angajați

808

EBITDA

93M

115M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+48.2% upside

Dividende

By Dow Jones

Următoarele câștiguri

30 iul. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-1.7B

5.7B

Deschiderea anterioară

82.91

Închiderea anterioară

74.19

Sentimentul știrilor

By Acuity

50%

50%

161 / 376 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Lantheus Holdings Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

16 iul. 2025, 23:56 UTC

Achiziții, Fuziuni, Preluări

Alimentation Couche-Tard Ends Bid to Buy Seven & I Holdings -- 2nd Update

16 iul. 2025, 23:43 UTC

Achiziții, Fuziuni, Preluări

Santos 2Q Output Rises 1% as Takeover Campaign Continues

16 iul. 2025, 23:00 UTC

Achiziții, Fuziuni, Preluări

Alimentation Couche-Tard Ends Bid to Buy Seven & I Holdings -- Update

16 iul. 2025, 22:38 UTC

Achiziții, Fuziuni, Preluări

Alimentation Couche-Tard Withdraws Seven & i Acquisition Proposal

16 iul. 2025, 23:44 UTC

Market Talk

Gold Steady; Geopolitical Tensions in Middle East Support -- Market Talk

16 iul. 2025, 23:42 UTC

Market Talk

Nikkei May Fall as Yen Strengthens -- Market Talk

16 iul. 2025, 23:24 UTC

Market Talk

Australian Job Market Data to Shape RBA Calls -- Market Talk

16 iul. 2025, 23:18 UTC

Achiziții, Fuziuni, Preluări

Santos Now Expects 2025 Production of 90 Million-95 Million BOE

16 iul. 2025, 23:18 UTC

Achiziții, Fuziuni, Preluări

Santos Cuts Top End of 2025 Production Guidance

16 iul. 2025, 23:17 UTC

Achiziții, Fuziuni, Preluări

Santos: Production Recovery Underway in Cooper Basin

16 iul. 2025, 23:17 UTC

Achiziții, Fuziuni, Preluări

Santos: Over 200 Wells, Several Upstream Compressors in Cooper Basin Shut In

16 iul. 2025, 23:17 UTC

Achiziții, Fuziuni, Preluări

Santos: Cooper Basin Production Impacted by Floods in 2Q

16 iul. 2025, 23:16 UTC

Achiziții, Fuziuni, Preluări

Santos: Pikka Phase 1 Project in Alasia 89% Complete

16 iul. 2025, 23:16 UTC

Achiziții, Fuziuni, Preluări

Santos Keeps 2025 Major Development Project Capex Guidance Unchanged

16 iul. 2025, 23:13 UTC

Achiziții, Fuziuni, Preluări

Santos Had Gearing of 20.5% at End-June, Excluding Operating Leases

16 iul. 2025, 23:13 UTC

Achiziții, Fuziuni, Preluări

Santos Says Moomba CCS Phase 1 Project Performing to Expectations

16 iul. 2025, 23:12 UTC

Achiziții, Fuziuni, Preluări

Santos Narrows 2025 Unit Production Cost Guidance to US$7.00-US$7.40/BOE

16 iul. 2025, 23:12 UTC

Achiziții, Fuziuni, Preluări

Santos 1H Free Cash Flow From Operations US$1.1 Billion

16 iul. 2025, 23:11 UTC

Achiziții, Fuziuni, Preluări

Santos 2Q Free Cash Flow From Operations US$620 Million

16 iul. 2025, 23:11 UTC

Achiziții, Fuziuni, Preluări

Santos 2Q Oil, Natural Gas Output 22.2 Million BOE

16 iul. 2025, 23:11 UTC

Achiziții, Fuziuni, Preluări

Santos 2Q Oil, Natural Gas Sales Volumes 23.9 Million BOE

16 iul. 2025, 23:11 UTC

Achiziții, Fuziuni, Preluări

Santos 2Q Oil, Natural Gas Sales Volumes Up 3% on 1Q

16 iul. 2025, 23:11 UTC

Achiziții, Fuziuni, Preluări

Santos 2Q Oil, Natural Gas Output Up 1% on 1Q

16 iul. 2025, 22:43 UTC

Market Talk

Alcoa Using High Costs of More Production to Battle Tariff -- Market Talk

16 iul. 2025, 22:35 UTC

Market Talk
Câștiguri

Global Equities Roundup: Market Talk

16 iul. 2025, 22:35 UTC

Market Talk
Câștiguri

Replacing Aluminum Imports With U.S. Production Not Seen Feasible -- Market Talk

16 iul. 2025, 22:33 UTC

Market Talk
Câștiguri

Alcoa Will Continue to Ship Aluminum Outside of the U.S. -- Market Talk

16 iul. 2025, 22:28 UTC

Market Talk
Câștiguri

Aluminum Price in U.S. Doesn't Offset Tariff Costs, Alcoa says -- Market Talk

16 iul. 2025, 22:22 UTC

Market Talk
Câștiguri

Market Talk Roundup: Latest on U.S. Politics

16 iul. 2025, 22:22 UTC

Market Talk
Câștiguri

Alcoa Considers Restart of Idle Capacity at Indiana Smelter -- Market Talk

Comparație

Modificare preț

Lantheus Holdings Inc Așteptări

Obiectiv de preț

By TipRanks

48.2% sus

Prognoză pe 12 luni

Medie 120.43 USD  48.2%

Maxim 137 USD

Minim 109 USD

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruLantheus Holdings Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

8 ratings

7

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

79.24 / 103.64Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Weak Bullish Evidence

Termen lung

Neutral Evidence

Sentiment

By Acuity

161 / 376 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Lantheus Holdings Inc

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.